A double conjugation strategy was implemented to produce an anti-fentanyl vaccine, which was predicated upon preformed-antibody-assisted antigen presentation. The new vaccine was found to reduce the psychoactive effects of fentanyl without the addition of the immunostimulant CpG oligodeoxynucleotide.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398699 | PMC |
| http://dx.doi.org/10.1039/d0cc02107e | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protocol for measuring anti-fentanyl antibodies in mouse serum by enzyme-linked immunosorbent assay.
STAR Protoc
December 2024
Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA. Electronic address:
Enzyme-linked immunosorbent assay (ELISA) offers an effective, inexpensive, and reliable approach for the analysis of humoral immune responses. Here, we describe a protocol for measuring anti-fentanyl antibodies generated by the immunization of mice with novel opioid vaccine candidates. We describe steps for coating BSA-fentanyl antigen and standard wells.
View Article and Find Full Text PDFScreening for Nonmedical Use and Misuse of Prescription Medication by Adolescents.
Subst Use Addctn J
December 2024
Division of Addiction Medicine, Boston Children's Hospital, Boston, MA, USA.
Article Synopsis
- * Among 716 adolescents analyzed, the rates of nonmedical use of prescription medications varied significantly across the screening tools, with the S2BI tool reporting the highest rate (8.5%).
- * The findings suggest that the misuse of prescription medications might be more common than previously thought, but the study also cautions that some results may be inaccurate and that refining screening questions could help clarify these behaviors.
Patent Review of Novel Biologics Targeting Opioid Use Disorder (2018-2024).
ACS Chem Neurosci
December 2024
Department of Pharmaceutical and Biomedical Sciences, Rudolph H. Raabe College of Pharmacy, Ohio Northern University, Ada, Ohio 45810, United States.
Article Synopsis
- In 2023, over 107,000 drug overdose deaths occurred in the U.S., with opioids responsible for approximately 80,000 of these fatalities, primarily due to synthetic opioids like fentanyl.
- New biologics, such as monoclonal antibodies and peptides, are emerging as innovative treatments for opioid overdose and opioid use disorder (OUD) by blocking opioids from affecting the central nervous system and reducing potential for abuse.
- The review highlights recent patents on these biologics and discusses their potential to prevent renarcotization, a risk where overdose patients can relapse into overdosing after being treated with naloxone.
Abuse potential of fentanyl and fentanyl analogues.
Bioimpacts
March 2024
College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, United States.
Introduction: In this perspective review, we evaluated the clinical management of fatal fentanyl overdose in several routes of administration, concentrating on both legally prescribed and illegally produced formulations.
Methods: A literature search was conducted on Web of Science, PubMed, and Google Scholar databases, using the following keywords: fentanyl, illicit fentanyl, deaths, misuse, abuse, and naloxone. We included only articles whose abstracts were available in English.
A Fentanyl Hapten-Displaying Lipid Nanoparticle Vaccine that Non-Covalently Encapsulates a TLR7/8 Agonist and T-Helper Epitope Induces Protective Anti-Fentanyl Immunity.
Angew Chem Int Ed Engl
October 2024
Department of Pharmaceutics, Ghent University, Belgium, Ottergemsesteenweg 460, Gent, 9000, Belgium.
Opioid use disorder - particularly involving fentanyl - has precipitated a public health crisis characterized by a significant increase in addiction and overdose-related deaths. Fentanyl-specific immunotherapy, which aims at inducing fentanyl-specific antibodies capable of binding fentanyl molecules in the bloodstream, preventing their entry in the central nervous system, is therefore gaining momentum. Conventional opioid designs rely on the covalent conjugation of fentanyl analogues to immunogenic carrier proteins that hold the inherent capacity of mounting immunodominant responses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!